No induction of antibodies in patients treated with the recombinant plasminogen activator reteplase (BM 06.022)

Fibrinolysis and Proteolysis

Volumn 11, Issue 5-6, 1997, Pages 259-264

  Kientsch Engel, R ^a   Bohm E ^a   Neubert, P ^a   Martin, U ^a   Fischer, S ^a   Smolarz, A ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; RETEPLASE; STREPTOKINASE;

ACUTE HEART INFARCTION; ALLERGENICITY; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; DRUG DETERMINATION; DRUG EFFECT; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOREGULATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0031445792     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80110-5     Document Type: Article

References (34)

1. Lee HS, Yule S, McKenzie A, et al. Hypersensitivity reactions to streptokinase in patients with high pre-treatment anti-streptokinase antibody and neutralisation titres. Eur Heart J 1993; 14: 1640-1643.
2. Jalihal S, Morris K. Antistreptokinase titres after intravenous streptokinase. Lancet 1990; 335: 184-185.
3. Fears R, Ferres H, Glasgow E, at al. Monitoring of streptokinase resistance titres in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG. Br Heart J 1992; 68: 167-170.
4. Gemill JD, Hogg KJ, Dunn FG, et al. Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase. Br Heart J 1994; 72: 222-225.
5. Buchalter MB, Suntharalingam G, Jennings I, et al. Streptokinase resistance: when might streptokinase administration be ineffective. Brit Heart J 1992; 68: 449-453.
6. Massel D, Turpie AG, Cairns JA, et al. Previous streptokinase therapy inhibits subsequent streptokinase thrombolysis. Circulation 1991; 84 (Suppl. II): 467.
7. Brügemann J, Van de Meer J, Bom VJJ, et al. Anti-streptokinase antibodies inhibit fibrinolytic effects of anistreplase in acute myocardial infarction. Am J Cardiol 1993; 72: 462-464.
8. GISSI-1 (Grupo Italiano per lo Studio della Supravivvoenza nel'Infarto Miocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
9. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
10. GUSTO (Global Utilisation of Streptokinase and Tissue Plasminogen Activator for Occluded coronary Arteries). An international randomized trial comparing thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
11. Lee HS, Cross SJ, Davidson R, et al. Raised levels of anti-streptokinase antibody and neutralisation titres from four days to 54 months after administration of streptokinase or anistreplase. Eur Heart J 1993; 14: 84-89.
12. Lynch M, Littler WA, Pentecost BL, Stockley RA. Immunoglobulin response to intravenous streptokinase in acute myocardial infarction. Brit Heart J 1991; 66: 139-142.
13. Elliott JM, Cross DB, Cederholm-Williams S, White HD. Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy. Am J Cardiol 1993; 71: 640-645.
14. Patel S, Jalihal S, Dutka DP, et al. Streptokinase neutralisation titres up to 866 days after intravenous streptokinase for acute myocardial infarction. Brit Heart J 1993; 70: 119-121.
15. White HD, Cross DB, William BF, et al. Safety and efficacy of readministration of thrombolytic treatment after acute myocardial infarction. Brit Heart J 1990; 64: 177-181.
16. Reed BR, Chen A, Tanswell P, et al. Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients. Thromb Haemost 1990; 64(2): 276-280.
17. Cugno M, Cicardi M, Colucci M, et al. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein. Thromb Haemost 1996; 76: 234-238.
18. Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S. Immunogenicity of recombinant DNA human insulin. Diabetologia 1983; 25: 465-469.
19. White GC II, McMillan CW, Blatt PM, Roberts HR. Factor VIII inhibitors: a clinical overview. Am J Hematol 1982; 13: 335-342.
20. Spiegel RJ, Spicehandler JR, Jacobs SL, Oden EM. Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A). Am J Med 1986; 80: 223-228.
21. Musch K, Wolf AS, Lauritzen C. Antibodies to human chorionic gonadotropin in humans. Clin Chim Acta 1981; 113: 95-100.
22. Bisset GW, Black A, Hilton PJ, Jones NF, Montgomery M. Polyuria associated with an antibody to vasopressin. Clin Sci Molec Med 1976; 50: 277-283.
23. Haddad JG Jr, Caldwell JG. Calcitonin resistance: clinical and immunologic studies in subjects with Paget's disease of bone treated with porcine and salmon calcitonins. J Clin Invest 1972; 51: 3133-3141.
24. Kohnert U, Rudolph R, Verheijen JH, et al. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Engineering 1992; 5: 93-100.
25. Martin U, Bader R, Böhm E, et al. BM 06022: A novel recombinant plasminogen activator. Cardiovascular Drug Reviews 1993; 11: 299-311.
26. Bode C, Kohler B, Smalling RW, Runge MS. Reteplase (r-PA): A novel recombinant plasminogen activator. Fibrinolysis 1995; 9(Suppl. I): 97-99.
27. Smalling RW, Bode C, Kalbfleisch J et al. and the RAPID Investigators. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91: 2725-2732.
28. Bode C, Smalling RW, Berg G, et al. for the RAPID II Investigators. Randomized comparison of coronary thrombolysis achieved with double bolus reteplase (r-PA) and front-loaded alteplase (rt-PA) in patients with acute myocardial infarction. Circulation 1996; 94: 891-898.
29. INJECT (International Joint Efficacy Comparison of Thrombolytics). Randomised, double-blind comparison to reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346: 329-336.
30. Murota T, Miyagawa M, Inoue Y, Yosikawa K. Antigenicity of GMK-527 (rt-PA). Jap Pharmacol Ther 1988; 16 (Suppl. 5): 143-153.
31. Buchalter MB. Is the development of antibodies of streptokinase clinically relevant? Drugs 1994; 48: 133-136.
32. Stewart TA, Hollingshead PG, Pitts SL, Chang R, Martin LE, Oakley H. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol Biol Med 1989; 6: 275-281.
33. Vanderschueren SMF, Stassen JM, Collen D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb Haemost 1994; 72: 297-301.
34. Colucci M, Cavallo L, Agnelli G, et al. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. Thromb Haemost 1993; 69: 466-472.